LRRC32 and neoplasm: This concept was corroborated by mouse model data in which increased tumor growth inhibition and reinvigorated CD8+ T-cell effector responses were demonstrated in mice treated with a combination of antibodies targeting PD-1 and the GARP:TGF-ß1 complex compared with either antibody alone (9).